{"id":1768,"date":"2022-12-02T13:27:00","date_gmt":"2022-12-02T12:27:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1768"},"modified":"2024-03-23T13:31:27","modified_gmt":"2024-03-23T12:31:27","slug":"8-liecivo-benralizumab-fasenra-na-liecbu-tazkej-eozinofilnej-astmy","status":"publish","type":"post","link":"https:\/\/www.niho.sk\/en\/8-liecivo-benralizumab-fasenra-na-liecbu-tazkej-eozinofilnej-astmy\/","title":{"rendered":"8: Lie\u010divo benralizumab (Fasenra) na lie\u010dbu \u0165a\u017ekej eozinofilnej astmy"},"content":{"rendered":"
    \n
  1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Fasenra (benralizumab) m\u00e1 sl\u00fa\u017ei\u0165, ako pr\u00eddavn\u00e1 terapia. M\u00e1 zni\u017eova\u0165 frekvenciu zhor\u0161enia astmy a zni\u017eova\u0165 nutn\u00fa d\u00e1vku or\u00e1lnych kortikosteroidov, ktor\u00e9 maj\u00fa mnoho ne\u017eiaducich \u00fa\u010dinkov.<\/p>\n\n\n\n

    Benralizumab sa pod\u00e1va podko\u017enou injekciou. Injekcia sa m\u00e1 pod\u00e1va\u0165 do stehna alebo brucha. Pacienti si m\u00f4\u017eu aplikova\u0165 liek sami po vy\u0161kolen\u00ed v technike pod\u00e1vania podko\u017enej injekcie. Aplikuje sa ako 1 injekcia ka\u017ed\u00fdch 8 t\u00fd\u017ed\u0148ov, prv\u00e9 3 d\u00e1vky ka\u017ed\u00e9 4 t\u00fd\u017edne.<\/p>\n\n\n\n

    Liek Fasenra bol registrovan\u00fd Eur\u00f3pskou liekovou agent\u00farou d\u0148a 18.1.2018.<\/p>\n\n\n\n

      \n
    1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Typick\u00fdmi pr\u00edznakmi astmy s\u00fa sipot, ka\u0161e\u013e, du\u0161nos\u0165 a tlak na hrudi. Pr\u00edznaky maj\u00fa epizodick\u00fd charakter. Trvaj\u00fa hodiny a\u017e dni a ustupuj\u00fa spont\u00e1nne, alebo po odstr\u00e1nen\u00ed sp\u00fa\u0161\u0165acieho podnetu, \u010di ako odpove\u010f na antiastmatick\u00fa lie\u010dbu. Naj\u010dastej\u0161\u00edmi sp\u00fa\u0161\u0165ac\u00edmi faktormi s\u00fa studen\u00fd vzduch, fyzick\u00e1 n\u00e1maha a vystavenie alerg\u00e9nom vo vdychovanom vzduchu. <\/p>\n\n\n\n

      Astma sa m\u00f4\u017ee rozvin\u00fa\u0165 v ka\u017edom veku, hoci v\u00e4\u010d\u0161ina astmatikov je diagnostikovan\u00e1 v detstve. Niektor\u00e9 podtypy, ako napr\u00edklad eozinofiln\u00e1 astma, m\u00e1 typick\u00fd za\u010diatok v dospelosti. Nelie\u010den\u00e1, alebo nedostato\u010dne lie\u010den\u00e1 astma m\u00f4\u017ee vies\u0165 k z\u00e1va\u017en\u00fdm komplik\u00e1ci\u00e1m ved\u00facim k smrti.<\/p>\n\n\n\n

      Pod\u013ea pacientskej organiz\u00e1cie Asthma UK s\u00fa pacienti obmedzen\u00ed vo svojom \u017eivote, neust\u00e1le musia sledova\u0165 pr\u00edtomnos\u0165 sp\u00fa\u0161\u0165ac\u00edch faktorov a to im riadi cel\u00fd \u017eivot.<\/p>\n\n\n\n

        \n
      1. Ako sa na benralizumab pozeraj\u00fa odborn\u00edci? <\/strong><\/li>\n<\/ol>\n\n\n\n

        Klinick\u00ed odborn\u00edci \u010delia dileme, ktor\u00fa by mohol benralizumab adresova\u0165. <\/p>\n\n\n\n

        Pacientov, ktor\u00ed s\u00fa relat\u00edvne stabiln\u00ed na or\u00e1lnych kortikosteroidoch sprev\u00e1dza mno\u017estvo ne\u017eiad\u00facich \u00fa\u010dinkov. O\u0161etruj\u00faci lek\u00e1r teda \u010del\u00ed dileme, \u010di d\u00e1vkovanie or\u00e1lnych kortikosteroidov zachova\u0165 spolu s ne\u017eiaducimi \u00fa\u010dinkami alebo ich zni\u017eova\u0165 a t\u00fdm riskova\u0165 zhor\u0161enie astmy, po ktorej by pacientom mohla by\u0165, na z\u00e1klade s\u00fa\u010dasn\u00fdch krit\u00e9ri\u00ed, indikovan\u00e1 biologick\u00e1 lie\u010dba.<\/p>\n\n\n\n

        Benralizumab by mal zni\u017eova\u0165 frekvenciu zhor\u0161enia astmy a z\u00e1rove\u0148 zni\u017eova\u0165 nutn\u00fa d\u00e1vku or\u00e1lnych kortikosteroidov.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (AstraZeneca AB) navrhuje hradi\u0165 lie\u010dbu benralizumabom (Fasenra) u dospel\u00fdch pacientov s \u0165a\u017ekou astmou. Z\u00e1rove\u0148 mus\u00ed plati\u0165, \u017ee pacienti sp\u013a\u0148aj\u00fa \u0161pecifick\u00e9 podmienky odv\u00edjaj\u00face sa od v\u00fdsledkov krvn\u00fdch testov a predch\u00e1dzaj\u00facej lie\u010dby kortikosteroidmi.<\/p>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie \u017eiada o \u00fahradu na \u00farovni 2105,64 \u20ac pre liek Fasenra 30 mg<\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da nevyhovie\u0165<\/strong> \u017eiadosti o kategoriz\u00e1ciu lieku Fasenra v indik\u00e1cii priedu\u0161kovej astmy, pokia\u013e:<\/p>\n\n\n\n

            \n
          • ned\u00f4jde k \u00faprave podmienok hradenia na z\u00e1klade odporu\u010dan\u00ed NIHO<\/mark><\/li>\n\n\n\n
          • a z\u00e1rove\u0148 dr\u017eite\u013e registr\u00e1cie neposkytne z\u013eavu vo v\u00fd\u0161ke, ktor\u00fa navrhuje NIHO, \u010do je jedin\u00e1 mo\u017enos\u0165 ako splni\u0165 krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti pod\u013ea \u00a77 z\u00e1kona 363\/2011 Z.z..<\/mark><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

            NIHO odpor\u00fa\u010da nevyhovie\u0165 \u017eiadosti o kategoriz\u00e1ciu lieku Fasenra v indik\u00e1cii priedu\u0161kovej astmy, pokia\u013e…<\/p>","protected":false},"author":3,"featured_media":1769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[27,26],"class_list":["post-1768","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-benralizumab","tag-fasenra"],"_links":{"self":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1768"}],"version-history":[{"count":0,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1768\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media\/1769"}],"wp:attachment":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}